Premium
Outcomes of carcinoma ex pleomorphic adenoma compared to de novo adenocarcinoma of major salivary glands
Author(s) -
Patel Evan J.,
Oliver Jamie R.,
Liu Cheng,
Tam Moses,
Givi Babak
Publication year - 2021
Publication title -
journal of surgical oncology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.201
H-Index - 111
eISSN - 1096-9098
pISSN - 0022-4790
DOI - 10.1002/jso.26289
Subject(s) - carcinoma ex pleomorphic adenoma , medicine , adenocarcinoma , lymph node , adenoma , salivary gland cancer , carcinoma , salivary gland , metastasis , oncology , pathology , gastroenterology , pleomorphic adenoma , cancer
Background and Objectives Carcinoma ex pleomorphic adenoma (CXPA) is a rare disease of the major salivary glands that remains poorly characterized. Our objective was to compare the clinical outcomes of patients with CXPA of the major salivary glands to those with de novo adenocarcinomas. Methods Review of the NCDB between 2004 and 2016 to compare cases of CXPA and adenocarcinoma of major salivary glands. Demographics, clinical characteristics, and survival were analyzed. Results We identified 1181 patients with CXPA and 3326 patients with adenocarcinoma of major salivary glands. Adenocarcinomas presented with higher rates of nodal metastasis (54.7% vs. 30.4%, p < .001). Five‐year survival of adenocarcinoma (55.8%) was worse than that of CXPA (68.5%, p < .001). When stratified by nodal status, there was no significant difference in 5‐year survival between CXPA and adenocarcinoma node‐negative (75.3% vs. 71.6%, respectively) and node‐positive (40.4% vs. 36.1%, respectively) patients. Conclusions CXPAs of the major salivary glands present at an earlier stage with lower rates of regional metastasis compared to adenocarcinomas. After controlling for lymph node metastases, the outcomes are quite similar.